Skip to main content

Table 2 Stage 2 Hurler and Hurler-Scheie patients

From: Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

patient

Type

Dx age (y)

Yrs on ERT

Height (cm)

Weight (kg)

Enroll. Age (y)

ID (mg/kg)

Genotype

Allele 1

Allele 2

202

H

0.7

8

101

19.6

9.0

1

p.W402X

p.W402X

203

H-S

4.9

1.7

104

19.1

6.1

3

p.R621X

het IVS9-12-4delCAGGCCCCG

204

H-S

5.0

9

144

37.1

14.8

1

p.R48del

p.P533R

205

H

1.1

1.5

112

24.7

5.0

1

c.494-1G>A

c.494-1G>A

206a

H

1.8

1

81

11.6

3.1

1

p.W402X

p.W402X

207

H

2.6

3

95

18.8

5.9

3

p.Q70X

p.W402X

211

H

2.4

0

78

11.4

2∙5

3

p.G208D

p.G208D

213

H-S

3.7

12

143

38.5

15.7

3

p.R383H

p.W402X

214

H

1.8

0

85

13.0

2.0

3

p.W402Term

p.W402Term

215

H

3.6

5.6

137

39.6

12.1

6

p.P533R

p.G208D

216

H

0.7

5.6

118

26.4

7.8

6

p.G208D

p.P533R

  1. apatient had failed bone marrow transplant 8 months prior to enrollment